Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
---|
04/13/2011 | CN102008723A Compound preparation of diclofenac sodium and triptan medicines for treating migraine |
04/13/2011 | CN102008722A Compound preparation of naproxen and triptan drugs for treating migraine |
04/13/2011 | CN102008628A Medicament for treating female genital tract virus infection and preparation method of sustained-release preparation of medicament |
04/13/2011 | CN102008538A Combined application of rhodiola sacra preparation and medicine resisting mental disease and tristimania for efficacy enhancement and toxicity reduction |
04/13/2011 | CN102008513A Method for controlling high swine fever by using nose atomization microecological preparation |
04/13/2011 | CN102008505A Bear gall preparation resistant to injuries of organ, such as muscle, and the like caused by statins |
04/13/2011 | CN102008428A Ophthalmic depot formulations for periocular or subconjunctival administration |
04/13/2011 | CN101461804B (+)-1-(3,4-dichlorrophenyl)-3-azabicyclo[3.1.0]hexane, compositions and uses thereof |
04/13/2011 | CN101365433B Iontophoresis preparation |
04/13/2011 | CN101291675B Novel anticancer concomitant drug |
04/13/2011 | CN101115709B Aminocarboxylic acid derivative and medicinal use thereof |
04/13/2011 | CA2740571A1 Synergistic effects between sphingosine-1-phosphate receptor antagonists and antimicrotubule agents |
04/12/2011 | US7923560 Delivery of immune response modifier compounds |
04/12/2011 | US7923509 Drug delivery compositions and medical devices containing block copolymer |
04/12/2011 | US7923429 Treatment for CD5+ B cell lymphoma |
04/12/2011 | US7923045 Compositions for alleviating inflammation and oxidative stress in a mammal |
04/12/2011 | US7923017 Modified Vaccinia Ankara virus variant |
04/12/2011 | CA2550023C Treatment of neuropathic pain |
04/12/2011 | CA2526771C Synthesis of high molecular weight iron-saccharidic complexes |
04/12/2011 | CA2488775C Fcyriia transgenic animal model for autoimmune disease |
04/12/2011 | CA2456172C Kidney-specific urate transporter and uses thereof |
04/12/2011 | CA2396542C Composition promoting lacrimal secretion |
04/12/2011 | CA2388363C Dna polymerase lambda and uses thereof |
04/12/2011 | CA2387107C Derivatives of dicarboxylic acid having pharmaceutical properties |
04/12/2011 | CA2362925C Methods of treatment of mitochondrial disorders |
04/12/2011 | CA2311409C Treatment with anti-erbb2 antibodies |
04/11/2011 | CA2771651A1 Compositions comprising tramadol and celecoxib in the treatment of pain |
04/07/2011 | WO2011041640A1 Olopatadine compositions and uses thereof |
04/07/2011 | WO2011041376A1 Modified granulocyte colony stimulating factor (g-csf) |
04/07/2011 | WO2011040651A1 Therapeutic agent for atopic dermatitis |
04/07/2011 | WO2011040597A1 Pharmaceutical composition containing medicament-containing fine particles and method for producing same |
04/07/2011 | WO2011040503A1 Method for recovery of sensitivity to anti-cancer agents in cancer cell that acquires resistance to anti-cancer agents |
04/07/2011 | WO2011040421A1 Screening method |
04/07/2011 | WO2011040052A1 Therapeutic agent for atopic dermatitis |
04/07/2011 | WO2011039337A1 Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof |
04/07/2011 | WO2011039282A1 Means and methods for treating ischemic conditions |
04/07/2011 | WO2011039175A1 Treatment of acne vulgaris, rosacea and androgenetic alopecia and cancer protection in smokers, obesity and diabetes mellitus |
04/07/2011 | WO2011038574A1 Oral dosage formulation containing both immediate-release and sustained-release drugs for treating neurodegenerative disorders |
04/07/2011 | US20110082482 Materials and Methods for Nerve Repair |
04/07/2011 | US20110082448 Pharmaceutical Compositions |
04/07/2011 | US20110082190 Nucleic Acids Encoding Anti-IL-12 Antibody |
04/07/2011 | US20110082108 Peptidomimetic Inhibitors of Post-Proline Cleaving Enzymes |
04/07/2011 | US20110082101 Combinations comprising epothilones and anti-metabolites |
04/07/2011 | US20110081366 Immunostimulatory nucleic acid molecules |
04/07/2011 | US20110081359 Alpha 5 beta 1 and its ability to regulate the cell survival pathway |
04/07/2011 | US20110081312 3'-[(2z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
04/07/2011 | DE102005018642B4 Verwendung von Verbindungen zur Hemmung der Glyoxalasen Use of compounds to inhibit the glyoxalases |
04/07/2011 | CA2776327A1 Treatment of disease with proteasome inhibitors |
04/07/2011 | CA2776288A1 Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof |
04/07/2011 | CA2773483A1 Olopatadine compositions and uses thereof |
04/06/2011 | EP2305836A1 Compositions, kits and methods for identification, assessment, prevention and therapy of cervical cancer |
04/06/2011 | EP2305823A1 Materials and methods relating to protein aggregation in neurodegenerative disease |
04/06/2011 | EP2305817A2 Anti-IL-12 antibodies, compositions, methods and uses |
04/06/2011 | EP2305808A1 Templated molecules and methods for using such molecules |
04/06/2011 | EP2305715A2 Monoclonal antibody to osteoprotegerin binding protein |
04/06/2011 | EP2305677A1 Alkyne-aryl-naphthyridin-4(1h)-one derivatives as type IV phosphodiesterase inhibitor |
04/06/2011 | EP2305654A1 Therapeutic agent for pain |
04/06/2011 | EP2305648A1 Amide derivatives useful as glucokinase activators |
04/06/2011 | EP2305324A1 Medical devices and applications of polyhydroxyalkanoate polymers |
04/06/2011 | EP2305307A1 Analgesic anti-inflammatory preparation for external application |
04/06/2011 | EP2305306A1 Neuroinvasion inhibitor |
04/06/2011 | EP2305305A1 Agent for induction/maintenance of remission |
04/06/2011 | EP2305304A1 Immunopotentiating agent comprising ep1 agonist |
04/06/2011 | EP2305291A1 Use of proteasome inhibitors for the treatment of HIV infections |
04/06/2011 | EP2305288A2 Acidic insulin preparations with improved stability |
04/06/2011 | EP2305285A1 Means and methods for treating ischemic conditions |
04/06/2011 | EP2305276A2 Processed lipoaspirate cells for use in therapy |
04/06/2011 | EP2305274A1 Use of WNT stimulators for treating demyelinating diseases |
04/06/2011 | EP2305265A1 Combinations comprising staurosporines |
04/06/2011 | EP2305259A1 Novel substituted benzimidazole dosage forms and method of using same |
04/06/2011 | EP2305256A1 Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers |
04/06/2011 | EP2305255A1 Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers |
04/06/2011 | EP2305251A2 Pharmaceutical compositions comprising clavulanic acid or derivative thereof for the treatment of sexual disorder |
04/06/2011 | EP2305245A1 Treatment of diseases associated with the use of antibiotics |
04/06/2011 | EP2305244A1 Treatment of diseases associated with the use of antibiotics |
04/06/2011 | EP2305243A1 Use of artemisinin and related compounds for treating diseases induced by human papilloma virus |
04/06/2011 | EP2305239A1 Retinal neuroprotection by ionic channel inhibitors regulated by the SUR subunit |
04/06/2011 | EP2305237A1 Therapeutic agent for male sterility |
04/06/2011 | EP2305233A1 Synergistic combinations comprising a renin inhibitor for cardiovascular diseases |
04/06/2011 | EP2305232A1 Synergistic combinations comprising a renin inhibitor for cardiovascular diseases |
04/06/2011 | EP2305231A1 Synergistic combinations comprising a renin inhibitor for cardiovascular diseases |
04/06/2011 | EP2305230A1 Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology |
04/06/2011 | EP2305229A1 Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology |
04/06/2011 | EP2305217A1 Method for the preparation of pharmaceutical compositions comprising a solid amorphous dispersion of cholesteryl ester transfer protein inhibitors |
04/06/2011 | EP2305213A2 The treatment of small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions |
04/06/2011 | EP2304444A1 Modulators of stat3 signalling |
04/06/2011 | EP2303352A2 Methods for processing substrates having an antimicrobial coating |
04/06/2011 | EP2303330A1 Pharmaceutical compositions for treatment of parkinson's disease |
04/06/2011 | EP2303329A1 Antifungal combination therapy |
04/06/2011 | EP2303328A1 Water soluble curcumin compositions for use in anti-cancer and anti-inflammatory therapy |
04/06/2011 | EP2303327A2 Niacin and nsaid for combination therapy |
04/06/2011 | EP2303298A2 Compositions comprising extracts from boswellia serrata |
04/06/2011 | EP2303274A1 Multiple myeloma treatments |
04/06/2011 | EP2303263A1 Use |
04/06/2011 | EP2303255A1 Pharmaceutical compositions useful for the treatment of cancers, in particular acute myeloid leukemia and acute promyelocytic leukemia |
04/06/2011 | EP2303254A2 Method for treating chronic wounds with an extracellular polymeric substance solvating system |
04/06/2011 | EP2303019A1 (6s)-5-methyltetrahydrofolic acid for therapy of tissue injury |
04/06/2011 | EP1878431B1 Medicinal agent for preventing progression of apoptotic and jugulating necrotic changes in the organism tissues |
04/06/2011 | EP1685832B1 Nerve regeneration promoters |
04/06/2011 | EP1404356B1 Method for designing cd10-activated prodrug compounds |